IDYA IDEAYA Biosciences, Inc. - 10-Q - (2025-11-04)

Financial Performance & Liquidity The company achieved a dramatic Q3 2025 turnaround, reporting $119.2 million net income ($1.35 basic EPS), compared to a $51.8 million loss in Q3 2024. Year-to-date (9M 2025), the net loss significantly narrowed to -$30.4 million (vs. -$144.2 million in 2024). Stock options were antidilutive for current EPS calculation periods.

Liquidity management involved deploying the Marketable Securities portfolio, which decreased from $1,005.1 million to $847.3 million. This contributed to a significant recovery in Cash and Equivalents, rising from a low poin

...

Join thousands of investors who never miss important market updates

Join